Evidence map›Paper›PMID 39992973›Full record

ArticlePloS one2025

Chemical nucleases are a robust alternative for RNase H cleavage of human ribosomal RNA.

Hagen Wesseling, Dennis Krug, Marvin Wehrheim, Michael W Göbel, Stefanie Kaiser

Abstract read
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Hagen WesselingInstitute of Pharmaceutical Chemistry, Goethe-University Frankfurt, Frankfurt/M, Germany.
Dennis KrugInstitute for Organic Chemistry and Chemical Biology, Goethe-University Frankfurt, Frankfurt/M, Germany.
Marvin WehrheimInstitute of Pharmaceutical Chemistry, Goethe-University Frankfurt, Frankfurt/M, Germany.ORCID 0009-0007-5495-6736
Michael W GöbelInstitute for Organic Chemistry and Chemical Biology, Goethe-University Frankfurt, Frankfurt/M, Germany.
Stefanie KaiserInstitute of Pharmaceutical Chemistry, Goethe-University Frankfurt, Frankfurt/M, Germany.ORCID 0000-0003-3224-7502

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Besides the abundant ribosomal and transfer RNA transcripts (rRNA and tRNA, respectively), there are tens of thousands of long coding (mRNA) and non-coding transcripts (lncRNA) within each cell whose modification profiles have not yet been elucidated. One reason for this is that most mRNAs and lncRNAs are low abundant and their purification prior to direct modification analysis by mass spectrometry (LC-MS) is highly challenging. State-of-the-art mRNA purification protocols are based on poly(A) enrichment with subsequent rRNA depletion using either magnetic pulldown assays or RNase H. While these methods are well suited for RNA sequencing, where residual rRNA content can be acceptable, LC-MS analysis of mRNA requires samples with less than 1% rRNA and higher yields, making the existing methods close to unaffordable. Thus, a new principle for low-cost (pre)mRNAs and lncRNAs preparation from total RNA will be beneficial for LC-MS analysis but also sequencing approaches. Here, we show that the use of ARRR (artificial ribosomal RNA remover: conjugates of standard DNA probes and a small-molecule chemical nuclease) is suitable for rRNA cleavage. In addition, ARRR has a higher target specificity compared to E. coli RNase H using regular DNA probes and only limited off-target RNA degradation is observed with ARRR. In summary, we present a promising tool with high potential to remove overly abundant rRNA, which might be used for enrichment of lncRNAs and (pre)mRNAs for downstream sequencing and MS-based analysis.

Indexed as

Ribonuclease HRNA, RibosomalEscherichia coliHumansRNA, Long NoncodingRibonuclease HRNA, Long NoncodingRNA, Ribosomal

Identifiers

PMID39992973
PMCPMC11849838

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.